LAVA Therapeutics N.V. announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.
[LAVA Therapeutics, N.V.]
7992332
{7992332:nan}
apa
50
1
164524
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
